FDA-Approved SB16 Biosimilar Demonstrates Equivalence to Prolia

Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships

May 29th 2025

By Skylar Jeremias

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.

British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits

May 28th 2025

By Skylar Jeremias

Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.

FDA Approves Starjemza as New Stelara Biosimilar

May 27th 2025

By Skylar Jeremias

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and gastrointestinal conditions.

Biosimilars Can Help Expand Early Access Anti-TNF Therapy in IBD

May 26th 2025

By Deana Ferreri, PhD

There's a need for early anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD), with new data showing that biosimilars can address cost barriers and enhance patient access and outcomes.

Automatic Biosimilar Substitution and Patient Education Advocated by Elena Wolff-Holz, MD

May 26th 2025

By Cameron Santoro

Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

The Top 5 Biosimilar Articles for the Week of May 19

May 23rd 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 19, 2025.

Differences in Psoriasis Treatment: Ustekinumab Dose Escalation vs Adalimumab, Etanercept Discontinuation

May 22nd 2025

By Cameron Santoro

Dose escalations were more frequent with ustekinumab in patients with psoriasis compared with adalimumab and etanercept, highlighting varied outcomes for dose optimization in psoriasis management.

What Stands in the Way of Biosimilar Use Across MENA Countries?

May 21st 2025

By Skylar Jeremias

Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.

Biosimilars Offer New Hope for European Patients Facing High Eculizumab Costs

May 20th 2025

By Skylar Jeremias

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome better access to care for a better price, similar to successes seen in other biosimilar markets, according to a review.

BioRationality: The Revised Indian Biosimilar Guidelines Finally Bring Rationality

May 19th 2025

By Sarfaraz K. Niazi, PhD